Explore the Potential with AI-Driven Innovation
Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.
The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by our partner Reaxense.
Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.
We employ our advanced, specialised process to create targeted libraries.
Fig. 1. The sreening workflow of Receptor.AI
Utilising molecular simulations, our approach thoroughly examines a wide array of proteins, tracking their conformational changes individually and within complexes. Ensemble virtual screening enables us to address conformational flexibility, revealing essential binding sites at functional regions and allosteric locations. Our rigorous analysis guarantees that no potential mechanism of action is overlooked, aiming to uncover new therapeutic targets and lead compounds across diverse biological functions.
Key features that set our library apart include:
partner
Reaxense
upacc
Q01538
UPID:
MYT1_HUMAN
Alternative names:
Myelin transcription factor I; PLPB1; Proteolipid protein-binding protein
Alternative UPACC:
Q01538; E1P5H0; F5H7M8; O94922; Q7Z5W2; Q9UPV2
Background:
Myelin transcription factor 1 (MTF1), also known as PLPB1 and Proteolipid protein-binding protein, is pivotal in the central nervous system's development. It binds to the promoter regions of genes encoding proteolipid proteins, influencing the maturation of neurons and oligodendroglia. MTF1 is crucial for modulating the balance between the proliferation of oligodendrocyte progenitors and their differentiation, alongside the up-regulation of myelin gene transcription.
Therapeutic significance:
Understanding the role of Myelin transcription factor 1 could open doors to potential therapeutic strategies.